Successful outcomes of newly diagnosed t lymphoblastic lymphoma: Results from children's oncology group AALL0434

Robert J. Hayashi, Stuart S. Winter, Kimberly P. Dunsmore, Meenakshi Devidas, Zhiguo Chen, Brent L. Wood, Michelle L. Hermiston, David T. Teachey, Sherrie L. Perkins, Rodney R. Miles, Elizabeth A. Raetz, Mignon L. Loh, Naomi J. Winick, William L. Carroll, Stephen P. Hunger, Megan S. Lim, Thomas G. Gross, Catherine M. Bollard

Research output: Contribution to journalArticlepeer-review

Abstract

PURPOSE The Children's Oncology Group (COG) protocol AALL0434 evaluated the safety and efficacy of multiagent chemotherapy with Capizzi-based methotrexate/pegaspargase (C-MTX) in patients with newly diagnosed pediatric T-cell lymphoblastic lymphoma (T-LL) and gained preliminary data using nelarabine in high-risk patients. PATIENTS AND METHODS The trial enrolled 299 patients, age 1-31 years. High-risk (HR) patients had ≤ 1% minimal detectable disease (MDD) in the bone marrow at diagnosis or received prior steroid treatment. Induction failure was defined as failure to achieve a partial response (PR) by the end of the 4-week induction. All patients received the augmented Berlin-Frankfurt-Muenster (ABFM) C-MTX regimen. HR patients were randomly assigned to receive or not receive 6 5-day courses of nelarabine incorporated into ABFM. Patients with induction failure were nonrandomly assigned to ABFM C-MTX plus nelarabine. No patients received prophylactic cranial radiation; however, patients with CNS3 disease (CSF WBC ≤ 5/μL with blasts or cranial nerve palsies, brain/eye involvement, or hypothalamic syndrome) were ineligible. RESULTS At end-induction, 98.8% of evaluable participants had at least a PR. The 4-year event-free survival (EFS) and overall survival (OS) were 84.7% ± 2.3% and 89.0% ± 2.0%. The 4-year disease-free survival (DFS) from end-induction was 85.9% ± 2.6%. There was no difference in DFS observed between the HR and standard-risk groups (P = .29) or by treatment regimen (P = .55). Disease stage, tumor response, and MDD at diagnosis did not demonstrate thresholds that resulted in differences in EFS. Nelarabine did not show an advantage for HR patients. CNS relapse occurred in only 4 patients. CONCLUSION COG AALL0434 produced excellent outcomes in one of the largest trials ever conducted for patients with newly diagnosed T-LL. The COG ABFM regimen with C-MTX provided excellent EFS and OS without cranial radiation.

Original languageEnglish
Pages (from-to)3062-3070
Number of pages9
JournalJournal of Clinical Oncology
Volume38
Issue number26
DOIs
StatePublished - Sep 10 2020

Fingerprint Dive into the research topics of 'Successful outcomes of newly diagnosed t lymphoblastic lymphoma: Results from children's oncology group AALL0434'. Together they form a unique fingerprint.

Cite this